News Column

New Engineering Study Findings Recently Were Reported by Researchers at Freiburg Institute for Advanced Studies (Glyco-engineering for...

August 26, 2014

New Engineering Study Findings Recently Were Reported by Researchers at Freiburg Institute for Advanced Studies (Glyco-engineering for biopharmaceutical production in moss bioreactors)

By a News Reporter-Staff News Editor at Life Science Weekly -- Investigators publish new report on Engineering. According to news reporting originating in Freiburg, Germany, by NewsRx journalists, research stated, "The production of recombinant biopharmaceuticals (pharmaceutical proteins) is a strongly growing area in the pharmaceutical industry. While most products to date are produced in mammalian cell cultures, namely Chinese hamster ovary cells, plant-based production systems gained increasing acceptance over the last years."

The news reporters obtained a quote from the research from Freiburg Institute for Advanced Studies, "Different plant systems have been established which are suitable for standardization and precise control of cultivation conditions, thus meeting the criteria for pharmaceutical production. The majority of biopharmaceuticals comprise glycoproteins. Therefore, differences in protein glycosylation between humans and plants have to be taken into account and plant-specific glycosylation has to be eliminated to avoid adverse effects on quality, safety, and efficacy of the products. The basal land plant Physcomitrella patens (moss) has been employed for the recombinant production of high-value therapeutic target proteins (e.g., Vascular Endothelial Growth Factor, Complement Factor H, monoclonal antibodies, Erythropoietin). Being genetically excellently characterized and exceptionally amenable for precise gene targeting via homologous recombination, essential steps for the optimization of moss as a bioreactor for the production of recombinant proteins have been undertaken."

According to the news reporters, the research concluded: "Here, we discuss the glyco-engineering approaches to avoid non-human N- and O-glycosylation on target proteins produced in moss bioreactors."

For more information on this research see: Glyco-engineering for biopharmaceutical production in moss bioreactors. Frontiers in Plant Science, 2014;5():1-7. Frontiers in Plant Science can be contacted at: Frontiers Research Foundation, PO Box 110, Lausanne, 1015, Switzerland (see also Engineering).

Our news correspondents report that additional information may be obtained by contacting E.L. Decker, Freiburg Inst Adv Studies, Freiburg, Germany. Additional authors for this research include J. Parsons and R. Reski.

Keywords for this news article include: Europe, Germany, Freiburg, Engineering

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Life Science Weekly

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters